Everything below concerns fatty acid oxidation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-01. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
The thymus continues to grow after birth, reaching the relative maximum size by puberty. It is most active in fetal and neonatal life. It increases to a mass of 20 to 50 grams by puberty. It then begins to decrease in size and activity in a process called thymic involution. After the first year of life the amount of T cells produced begins to fall. Fat and connective tissue fill a part of the thymic volume. During involution, the thymus decreases in size and activity. Fat cells are present at birth, but increase in size and number markedly after puberty, invading the gland from the walls between the lobules first, then into the cortex and medulla. This process continues into old age, where whether with a microscope or with the human eye, the thymus may be difficult to detect, although typically weighs 5–15 grams. Additionally, there is an increasing body of evidence showing that age-related thymic involution is found in most, if not all, vertebrate species with a thymus, suggesting that this is an evolutionary process that has been conserved.[40] The atrophy is due to the increased circulating level of sex hormones, and chemical or physical castration of an adult results in the thymus increasing in size and activity. Severe illness or human immunodeficiency virus infection may also result in involution.
== Biodegradability == The biodegradation of PLGA makes it useful for plenty of medical applications with PLGA. For example, a 75:25 lactide to glycolide PLGA ratio can be made as microspheres that degrade via bulk erosion, with polymer composition playing a role in the degradation behavior. This would allow degradation throughout the whole polymer to occur equally. PLGA is also widely used in injectable forms developed to have eroding systems. This form can be used in Lupron Depot. To achieve this, PLGA is dissolved with an organic water-miscible solvent approved by the FDA to create a homogeneous solution or suspension. When injected, the solvent diffuses into the surrounding aqueous environment, causing PLGA to precipitate and form a solid depot. The encapsulated drug is released as the polymer gradually degrades. However, a problem that may occur during the initial injection is that the drug may be released in a quick burst instead of gradually.
== External links == "Understanding the RNA World". Exploring Life's Origins. Exploring Origins Project. Ferris, James P. "The Formation of the RNA World". The New York Center for Studies of the Origins of Life, Rensselaer Polytechnic Institute. Archived from the original on March 1, 2012. Altman, Sidney (2001). "The RNA World". NobelPrize.org. Nobel Media. Kuska, Robert (June 2002). "A World Apart" (PDF). HHMI Bulletin. Howard Hughes Medical Institute. pp. 14–19. Archived (PDF) from the original on 2004-05-22. Cech, Thomas R. (2004). "Exploring the New RNA World". NobelPrize.org. Nobel Media. Sutherland JD (April 2010). "Ribonucleotides". Cold Spring Harbor Perspectives in Biology. 2 (4) a005439. doi:10.1101/cshperspect.a005439. PMC 2845210. PMID 20452951. "The Origins of the RNA World". YouTube. Library of Congress. August 5, 2016.
Sources: en.wikipedia.org
==== Elimination ==== Lisinopril leaves the body completely unchanged in the urine. The half-life of lisinopril is 12 hours, and is increased in people with kidney problems. While the plasma half-life of lisinopril has been estimated between 12 and 13 hours, the elimination half-life is much longer, at around 30 hours. The full duration of action is between 24 and 30 hours. Lisinopril is the only water-soluble member of the ACE inhibitor class and thus has no metabolism by the liver.
==== Dose ==== A milliliter of pure GBL metabolizes to the equivalent 1.65 g of NaGHB, the common form, so doses are measured in the single milliliter range, either taken all at once or sipped over the course of a night.
=== REDEFINE 1 === In June 2025, results were published in the New England Journal of Medicine on REDEFINE 1, a 68-week, double-blind, Phase III clinical trial enrolling 3,417 participants, testing weekly cagrilintide 2.4 mg and semaglutide 2.4 mg individually and together versus placebo in obese/overweight subjects with comorbidities. People treated with CagriSema lost 20.4% of their body weight over 68 weeks, versus 11.5% with cagrilintide 2.4 mg alone, 14.9% with semaglutide 2.4 mg alone, and 3.0% with placebo.
Valine (symbol Val or V) is an α-amino acid that is used in the biosynthesis of proteins. It contains an α-amino group (which is in the protonated −NH3+ form under biological conditions), an α-carboxylic acid group (which is in the deprotonated −COO− form under biological conditions), and a side chain isopropyl group, making it a non-polar aliphatic amino acid. Valine is essential in humans, meaning the body cannot synthesize it; it must be obtained from dietary sources which are foods that contain proteins, such as meats, dairy products, soy products, beans and legumes. It is encoded by all codons starting with GU (GUU, GUC, GUA, and GUG).
Sources: en.wikipedia.org
=== Legal status === In November 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Augtyro, intended for the treatment of people whose solid tumors have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, or people with ROS1-positive advanced non-small cell lung cancer (NSCLC). The applicant for this medicinal product is Bristol-Myers Squibb Pharma EEIG. Repotrectinib was authorized for medical use in the European Union in January 2025.
Isoelectric focusing (IEF), also known as electrofocusing, is a technique for separating different charged molecules by differences in their isoelectric point (pI). It is a type of zone electrophoresis usually performed on proteins in a gel that takes advantage of the fact that overall charge on the molecule of interest, i.e. the net charge density, is a function of the pH of its surroundings.
== Checkups == Although the symptoms of diabetes mellitus such as frequent urination, thirstiness, greater appetites and inactiveness are easily visible, frequent checking of the dog for the disease is required. The dog's body weight should be determined and calculated once every two weeks using weight scale. The daily caloric requirement by the dog's body and BCS should also be determined using a scale as part of dietary management in maintaining average body weight. The protein intake by the dog should also be considered and checked twice a month. Blood pressure of the dog should also be constantly and daily checked in order to predict any future occurrence. The blood sugar level may also be checked using glucometer to check the glucose level in the body of the dog.
=== EC 1.8.1 With NAD+ or NADP+ as acceptor === EC 1.8.1.1: deleted EC 1.8.1.2: sulfite reductase (NADPH) EC 1.8.1.3: deleted; reaction shown to be due to EC 1.14.13.8, flavin-containing monooxygenase EC 1.8.1.4: dihydrolipoyl dehydrogenase EC 1.8.1.5: 2-oxopropyl-CoM reductase (carboxylating) EC 1.8.1.6: cystine reductase EC 1.8.1.7: glutathione-disulfide reductase EC 1.8.1.8: protein-disulfide reductase EC 1.8.1.9: thioredoxin-disulfide reductase EC 1.8.1.10: CoA-glutathione reductase EC 1.8.1.11: asparagusate reductase EC 1.8.1.12: trypanothione-disulfide reductase EC 1.8.1.13: bis-γ-glutamylcystine reductase EC 1.8.1.14: CoA-disulfide reductase EC 1.8.1.15: mycothione reductase EC 1.8.1.16: glutathione amide reductase EC 1.8.1.17: dimethylsulfone reductase EC 1.8.1.18: NAD(P)H sulfur oxidoreductase (CoA-dependent) EC 1.8.1.19: sulfide dehydrogenase EC 1.8.1.20: 4,4′-dithiodibutanoate disulfide reductase EC 1.8.1.21: dissimilatory dimethyldisulfide reductase EC 1.8.1.22: dissimilatory sulfite reductase
== Function == Erection occurs through parasympathetic innervation, which allows engorgement of the corporal bodies; the bulbospongiosus and ischiocavernosus muscles at the root compress the veins and prevent blood draining from the corpora cavernosa. Following ejaculation, sympathetic stimulation constricts the coiled helicine arteries and the two muscles relax, allowing the cavernous spaces to drain and the penis to become flaccid. The strength and inflexibility of the tunica albuginea covering the corpora blocks venous return and is therefore responsible for maintaining rigidity during an erection.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.